Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BettER: Biomarker Driven Early Therapeutic Selection in HR+ HER2- Metastatic Breast Cancer
NCT05977036Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2024
- Primary completion
- Sep 2034
- Countries
- 1
01
Overview
Open-label trial in breast cancer (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Progression-Free Survival in patients with suppressed TKa levels at 7 years, Clinical Benefit Rate in patients with suppressed TKa levels at 7 years and 1 more. Started Sep 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05977036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977036.